Home » Stocks » GLTO

Galecto, Inc. (GLTO)

Stock Price: $12.60 USD 0.33 (2.69%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 313.35M
Revenue (ttm) n/a
Net Income (ttm) -47.88M
Shares Out 24.59M
EPS (ttm) -1.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $12.60
Previous Close $12.27
Change ($) 0.33
Change (%) 2.69%
Day's Open 12.37
Day's Range 12.35 - 12.92
Day's Volume 9,393
52-Week Range 12.20 - 16.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today anno...

GlobeNewsWire - 3 weeks ago

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today anno...

GlobeNewsWire - 1 month ago

Successfully completed listing on US Nasdaq and raised over $ 150 million during recent IPO and preceding crossover round

GlobeNewsWire - 1 month ago

BOSTON and COPENHAGEN, Denmark, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, a...

GlobeNewsWire - 2 months ago

BOSTON and COPENHAGEN, Denmark, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibros...

Seeking Alpha - 2 months ago

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to rais...

Other stocks mentioned: ALGM, AVIR, BDSX, GATO, LESL, LU, MAX, ROOT, SQZ
Seeking Alpha - 2 months ago

Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed.

Other stocks mentioned: ACICU, AVIR, DSACU, LESL, LUXAU, MAX, ROOT
GlobeNewsWire - 2 months ago

BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the b...

Seeking Alpha - 3 months ago

Galecto has filed proposed terms for an $85 million U.S. IPO. The firm is development treatments for various fibrosis diseases.

About GLTO

Galecto, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galect... [Read more...]

Industry
Biotechnology
IPO Date
Oct 29, 2020
CEO
Hans T. Schambye
Employees
23
Stock Exchange
NASDAQ
Ticker Symbol
GLTO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Galecto stock is "Strong Buy." The 12-month stock price forecast is 24.75, which is an increase of 96.43% from the latest price.

Price Target
$24.75
(96.43% upside)
Analyst Consensus: Strong Buy